Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults
interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
Goepfert, Paul A
Fu, Bo
Chabanon, Anne-Laure
Bonaparte, Matthew I
Davis, Matthew G
Essink, Brandon J
Frank, Ian
Haney, Owen
Janosczyk, Helene
Keefer, Michael C
Koutsoukos, Marguerite
Kimmel, Murray A
Masotti, Roger
Savarino, Stephen J
Schuerman, Lode
Schwartz, Howard
Sher, Lawrence D
Smith, Jon
Tavares-Da-Silva, Fernanda
Gurunathan, Sanjay
Granados, Carlos A Diaz
de Bruyn, Guy
text
monographic
eng
Paul A Goepfert [and twenty two others]
Lancet Infect Dis . 2021 Apr 19; S1473-3099 (21) 00147-X.
doi: 10.1016/S1473-3099(21)00147-X
COVID-19 Vaccines
immunology
Placebo Effect
210505
20210505150229.0
D0001C000194